Lipid lowering algorithm

This episode delivers a high-level briefing on the shifting paradigm in lipid management, bridging the 2026 American Heart Association and 2025 American Association of Clinical Endocrinology guidelines. We analyze the transition from percentage-based reductions to strict, risk-stratified absolute targets for low-density lipoprotein cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol. The discussion details practical implementation of the novel PREVENT risk calculator, universal lipoprotein a screening thresholds, and advanced coronary artery calcium scoring for risk reclassification. Finally, we map out the mandated pharmacological escalation pathway, covering statins, ezetimibe, PCSK9 inhibitors, inclisiran, bempedoic acid, and targeted hypertriglyceridemia interventions.